5.38 Interest of Early Determination of Bone Marrow Minimal Residual Disease by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: the Experience of the CLL2007FMP, an Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine, Cyclophosphamide, and Rituximab versus Fludarabine, Cyclophosphamide, and MabCampath in Previously Untreated B-Chronic Lymphocytic Leukemia Patients
Title:
5.38 Interest of Early Determination of Bone Marrow Minimal Residual Disease by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: the Experience of the CLL2007FMP, an Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine, Cyclophosphamide, and Rituximab versus Fludarabine, Cyclophosphamide, and MabCampath in Previously Untreated B-Chronic Lymphocytic Leukemia Patients
Author:
Letestu, Remi LeprĂȘtre, Stephane Arnoulet, Christine Baseggio, Lucille Campos, Lydia Chatelain, Bernard Drenou, Bernard Jacob, Marie-Christine Legac, Eric Le Garff-Tavernier, Magali Ticchioni, Michel Robillard, Nelly Delepine, Roselyne Levy, Vincent Katsahian, Sandrine Leblond, Veronique Cymbalista, Florence Feugier, Pierre